07.08.13
ChromaDex Corp., Irvine, CA, will enter a three-year marketing deal worth at least $3.5 million with Thorne Research Inc., Sandpoint, ID, for ChromaDex's recently launched NiagenT—a novel, patented, branded nicotinamide riboside (NR) ingredient.
Under the terms of the agreement, Thorne Research receives marketing rights for NiagenT for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the U.S. and Canada. ChromaDex will receive a royalty on sales of Thorne Research products that will contain NiagenT. In addition, Thorne Research will collaborate with ChromaDex on future human clinical trials of NiagenT.
“Mitochondrial energy production is critical for efficient metabolism of fats and carbohydrates, weight management, athletic performance, cardiovascular health and neuroprotection,” said Robert Rountree, M.D., chief medical officer of Thorne Research. “Research has shown that oral nicotinamide riboside, a compound naturally found in the diet, can significantly optimize mitochondrial function by increasing intracellular levels of NAD+. In addition to improving the overall redox state of the cell, an increase in NAD+ results in activation of SIRT1 and PGC-1alpha, cellular proteins that play a major role in mitochondrial biogenesis, glucose regulation and protection against age-related disease. Studies have shown that nicotinamide riboside increases muscle endurance, protects nerve cells from injury, improves insulin sensitivity, lowers serum cholesterol and limits diet-induced obesity. Nicotinamide riboside also represents the next generation of vitamin B3, providing the benefits of niacin but without the disturbing flush that impairs patient compliance.”
Frank Jaksch, ChromaDex founder and CEO, stated, “ We are proud to have Thorne Research, a highly regarded industry innovator, as our first channel partner for NiagenT, our branded nicotinamide riboside.”
According to the companies, NiagenT has the potential to become a part of the portfolio of B-vitamin ingredients included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula and food and beverage products.
Under the terms of the agreement, Thorne Research receives marketing rights for NiagenT for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the U.S. and Canada. ChromaDex will receive a royalty on sales of Thorne Research products that will contain NiagenT. In addition, Thorne Research will collaborate with ChromaDex on future human clinical trials of NiagenT.
“Mitochondrial energy production is critical for efficient metabolism of fats and carbohydrates, weight management, athletic performance, cardiovascular health and neuroprotection,” said Robert Rountree, M.D., chief medical officer of Thorne Research. “Research has shown that oral nicotinamide riboside, a compound naturally found in the diet, can significantly optimize mitochondrial function by increasing intracellular levels of NAD+. In addition to improving the overall redox state of the cell, an increase in NAD+ results in activation of SIRT1 and PGC-1alpha, cellular proteins that play a major role in mitochondrial biogenesis, glucose regulation and protection against age-related disease. Studies have shown that nicotinamide riboside increases muscle endurance, protects nerve cells from injury, improves insulin sensitivity, lowers serum cholesterol and limits diet-induced obesity. Nicotinamide riboside also represents the next generation of vitamin B3, providing the benefits of niacin but without the disturbing flush that impairs patient compliance.”
Frank Jaksch, ChromaDex founder and CEO, stated, “ We are proud to have Thorne Research, a highly regarded industry innovator, as our first channel partner for NiagenT, our branded nicotinamide riboside.”
According to the companies, NiagenT has the potential to become a part of the portfolio of B-vitamin ingredients included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula and food and beverage products.
